Photo from Ajay Major/LinkedIn
Jul 31, 2024, 11:52
Ajay Major: PFS benefit in AMPLIFY Phase III trial in CLL
Ajay Major, Lymphoma Faculty at the CU School of Medicine, shared on X:
“Press release now out: PFS benefit in AMPLIFY Phase III trial of fixed-duration acala + venetoclax +/- obinutuzumab vs investigator choice of CIT. Would be great to have a 2nd-gen BTKi plus ven time-limited combo approved.”
Read further.
Source: Ajay Major/X